| First Author | Rosahl TW | Year | 2006 |
| Journal | Mol Cell Neurosci | Volume | 33 |
| Issue | 1 | Pages | 47-56 |
| PubMed ID | 16870468 | Mgi Jnum | J:116524 |
| Mgi Id | MGI:3694409 | Doi | 10.1016/j.mcn.2006.06.006 |
| Citation | Rosahl TW, et al. (2006) A genetically modified mouse model probing the selective action of ifenprodil at the N-methyl-D-aspartate type 2B receptor. Mol Cell Neurosci 33(1):47-56 |
| abstractText | Selective antagonism of N-methyl-d-aspartate (NMDA) 2B subunit containing receptors has been suggested to have potential therapeutic application for multiple CNS disorders. The amino terminal NR2B residues 1 to 282 were found to be both necessary and sufficient for the binding and function of highly NR2B subunit specific antagonists like ifenprodil and CP-101,606. Using a genetic approach in mice, we successfully replaced the murine NR2B gene function by 'knocking-in' (KI) a chimeric human NR2A/B cDNA containing the minimal domain abolishing ifenprodil binding into the endogenous NR2B locus. Patch-clamp recording from hippocampal cultures of the NR2B KI mice demonstrated that their NMDA receptors have reduced sensitivity to both ifenprodil and CP-101,606, as predicted, but also have a lower affinity for glycine. The NR2B KI mice exhibited normal locomotor activity making this ifenprodil-insensitive mouse model a valuable tool to test the specificity of NR2B selective antagonists in vivo. |
